

Available online at www.sciencedirect.com

# **Resuscitation Plus**

journal homepage: www.elsevier.com/locate/resuscitation-plus

# **Clinical paper**

# Factors associated with survival and neurologic outcome after in-hospital cardiac arrest in children: A cohort study



RESUSCITATION

Tania M. Shimoda-Sakano<sup>a,\*</sup>, Edison F. Paiva<sup>b</sup>, Cláudio Schvartsman<sup>a</sup>, Amelia G. Reis<sup>a</sup>

# Abstract

**Aim**: In-hospital paediatric cardiopulmonary resuscitation (CPR) survival has been improving in high-income countries. This study aimed to analyse factors associated with survival and neurological outcome after paediatric CPR in a middle-income country.

**Methods**: This observational study of in-hospital cardiac arrest using Utstein-style registry included patients <18 years old submitted to CPR between 2015 and 2020, at a high-complexity hospital. Outcomes were survival and neurological status assessed using Paediatric Cerebral Performance Categories score at prearrest, discharge, and after 180 days.

**Results**: Of 323 patients who underwent CPR, 108 (33.4%) survived to discharge and 93 (28.8%) after 180 days. In multivariable analysis, lower survival at discharge was associated with liver disease (OR 0.060, CI 0.007–0.510, p = 0.010); vasoactive drug infusion before cardiac arrest (OR 0.145, CI 0.065–0.325, p < 0.001); shock as the immediate cause (OR 0.183, CI 0.069–0.486, p = 0.001); resuscitation > 30 min (OR 0.070, CI 0.014–0.344, p = 0.001); and bicarbonate administration during CPR (OR 0.318, CI 0.130–0.780, p = 0.01). The same factors remained associated with lower survival after 180 days. Neurological outcome was analysed in the 93 survivors after 180 days following CPR. Prearrest neurological dysfunction was observed in 31.4%, and neurological prognosis was favourable in 79.7% at discharge and similar after 180 days.

**Conclusion**: In-hospital paediatric cardiac arrest patients with complex chronic conditions had lower survival associated with liver disease, shock as cause of cardiac arrest, vasoactive drug infusion before cardiac arrest, bicarbonate administration during CPR, and prolonged resuscitation. Most survivors had favourable neurological outcome.

Keywords: Cardiac arrest, Cardiopulmonary resuscitation, In-hospital cardiac arrest, Pediatric, Prognostic factors, Neurological outcome

# Introduction

Cardiac arrest is an infrequent event in the paediatric population compared to that in adults.<sup>1,2</sup> The estimated annual incidence in the United States is 292,000 cases in adults and 15,200 cases in children, posing a major challenge for conducting paediatric studies with robust data.<sup>2</sup>

The literature reports great variation in paediatric cardiac arrest outcomes due to different populations analysed, hospital and department characteristics, different outcomes, level of development between countries, and study periods.<sup>1,3–7</sup> However, there is a trend toward improved survival to discharge rate as high as 43% to 45%, in high-income countries.<sup>8,9</sup> In addition to survival, reports on neurolog-

ical prognosis have gained increasing importance in paediatric resuscitation studies.  $^{1,3,9\!-13}$ 

An increased paediatric population with pre-existing chronic conditions has also been observed, reaching more than 50% of patients in paediatric intensive care.<sup>14,15</sup> Another subgroup of the paediatric population with increasing importance is patients with complex chronic conditions, defined as any condition expected to last at least 12 months, involving one major organ or with systemic involvement, requiring specialized follow-up, or involving hospitalization in a tertiary centre.<sup>16</sup> This population has a high mortality rate and a greater need for intensive care and length of stay<sup>17</sup>; however, the factors associated with the prognosis of cardiac arrest in children with complex chronic conditions are unclear.

Most studies on in-hospital paediatric cardiac arrest involve large cardiopulmonary resuscitation (CPR) registries, multicentre studies,

\* Corresponding author at: R. Santa Justina, 215 ap 62, CEP 04545-041 São Paulo, Brazil. E-mail address: tania.shimoda@hc.fm.usp.br (T.M. Shimoda-Sakano).

https://doi.org/10.1016/j.resplu.2022.100354

Received 20 November 2022; Received in revised form 26 December 2022; Accepted 28 December 2022

2666-5204/© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

and single-centre studies with voluntary participation, with data especially concentrated in high-income countries.<sup>3,4,18-25</sup> The epidemiology of paediatric cardiac arrest was identified by the International Liaison Committee on Resuscitation as a priority area for larger studies.<sup>26</sup>

The primary objective of this study was to evaluate the factors associated with survival at discharge and after 180 days. The secondary objective was to analyse the neurological outcome.

# **Methods**

#### Design, setting and patients

This observational study used data derived from the hospital cardiac arrest record that followed the Utstein style<sup>27</sup> and had been filled out by the professionals responsible for patient care. The Paediatric Cerebral Performance Category (PCPC) score was used to assess neurological function through the analysis of medical records and interviews with professionals and family members. Neurological

function was classified as favourable (Paediatric Cerebral Performance Category 1 or 2 or no change from baseline) or unfavourable (Paediatric Cerebral Performance Category  $\geq$  3). Only the index event was considered.

The data were collected during the period between January 1, 2015 and December 31, 2020 from a single center, which is a quaternary university public paediatric hospital with a rapid response team and a paediatric early warning system. Extracorporeal cardiopulmonary resuscitation is not offered during CPR. It is located in Sao Paulo, Brazil, in the biggest hospital complex of the country.

The study was approved by the local ethics and research committee, CAAE: 29237420.7.0000.0068. A presumed consent form was used due to the difficulty in obtaining a signature in extreme emergency situations.<sup>28–30</sup>

#### Participants

The study population included patients <18 years of age undergoing in-hospital cardiac arrest. The exclusion criteria were patients who did not receive CPR, out of hospital cardiac arrest, children with sur-



Fig. 1 – Patient inclusion flowchart and neurological outcome. CPR: cardiopulmonary resuscitation, ROSC: return of spontaneous circulation.

gical cardiac diseases, trauma patients, and cardiac arrest in the delivery room. Trauma patients and patients with surgical heart diseases were treated in other sectors of the hospital complex.

Of the initial 447 patients, 323 were eligible, corresponding to the study population.

#### Independent variables

The data on the following variables were collected: sex, age, day of the week, period of the day and year when the cardiac arrest occurred, complex chronic conditions category, event location, interventions in place at time of cardiac arrest (mechanical ventilation, vasoactive drug infusion), immediate cause of cardiac arrest, duration of CPR attempt, initial cardiac rhythm, and drugs used during CPR (adrenaline, bicarbonate, and calcium). Paediatric Cerebral Performance Category score was evaluated in the periods prearrest, at discharge, and after 180 days. Dose, time, and interval of adrenaline administration; CPR quality parameters; and post-cardiac arrest care variables were not analysed.

#### Outcomes

Outcomes included survival and neurological status at hospital discharge and after 180 days. Neurological function was assessed using the Paediatric Cerebral Performance Category score prearrest, at discharge, and after 180 days.

#### Statistical analyses

Statistical analyses were conducted using IBM SPSS software version 24 and R software version 3.5. Outcomes were compared between groups using the Pearson's chi-square test or Fisher's exact test for categorical variables. Univariable and multivariable logistic regression analyses were performed to assess the effect of each one of the factors on survival to hospital discharge and survival at 180 days. All individual factors with statistical significance in the univariable analysis and *p*-value <0.10 were eligible for inclusion in the logistic regression model. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated for each model. *P* values less than 0.05 were considered significant.

# **Results**

Of 323 patients who underwent CPR, 229 (70.9%) achieved return of spontaneous circulation (ROSC), 112 (34.7%) survived after 30 days, 109 (33.7%) to discharge, and 93 (28.8%) after 180 days (Fig. 1).

The characteristics of the study population are presented in Table 1. The following variables showed statistically significant differences: complex chronic conditions category, event location, day of the week and time of cardiac arrest, interventions prior to CPR (vasoactive drug infusion and mechanical ventilation), immediate car-

#### Table 1 - Characteristics of survivors versus non-survivors at hospital discharge.

	Total	Survival to hospital	I discharge	
Characteristics	n (%)	Survivors n (%)	No survivors n (%)	P-value
	N = 323	N = 109	N = 214	
Year				
2015	65 (20.1)	24 (22.0)	41 (19.2)	0.19
2016	64 (19.8)	21 (19.3)	43 (20.1)	
2017	59 (18.3)	15 (13.8)	44 (20.6)	
2018	43 (13.3)	10 (9.2)	33 (15.4)	
2019	47 (14.6)	20 (18.3)	27 (12.6)	
2020	45 (13.9)	19 (17.4)	26 (12.1)	
Age group				
<1 month	74 (22.9)	19 (17.4)	55 (25.7)	0.06
$\geq$ 1 month–1 year	119 (36.8)	50 (45.9)	69 (32.2)	
$\geq$ 1–12 years	107 (33.1)	35 (32.1)	72 (33.6)	
$\geq$ 12 years old	23 (7.1)	5 (4.6)	18 (8.4)	
Sex				
Female	164 (50.8)	61 (56)	103 (48.1)	0.18
Male	159 (49.2)	48 (44)	111 (51.9)	
Complex chronic condition			, , , , , , , , , , , , , , , , , , ,	
No	12 (3.7)	8 (7.3)	4 (1.9)	0.01
Yes	311 (96.3)	101 (92.7)	210 (98.1)	
Disease categories				
Prenatal condition or complications	83 (25.7)	26 (23.9)	57 (26.6)	0.002
Hepatic	77 (23.8)	14 (12.8)	63 (29.4)	
Genetic or metabolic	59 (18.3)	21 (19.3)	38 (17.8)	
Oncohematologic or immunologic	27 (8.4)	10 (9.2)	17 (7.9)	
Other	65 (20.1)	30 (27.5)	35 (16.4)	
Event location		, ,	· · ·	
PICU	259 (80.2)	77 (70.6)	182 (85.0)	0.005
Emergency department	29 (9.0)	11 (10.1)	18 (8.4)	
OR/Endoscopy/Diagnostic area	25 (7.7)	15 (13.8)	10 (4.7)	
Wards	10 (3.1)	6 (5.5)	4 (1.9)	
		· · ·	· · ·	

(continued on next page)

Table 1 (continued)				
	Total	Survival to hospital disch	arge	
Characteristics	n (%)	Survivors n (%)	No survivors n (%)	P-value
	N = 323	N = 109	N = 214	
Period of the week				
Weekday	237 (73.4)	83 (76.1)	154 (72.0)	0.42
Weekend	86 (26.6)	26 (23.9)	60 (28.0)	
Period of the day				
Day (7 am–6:59 pm)	184 (57.0)	77 (70.6)	107 (50.0)	<0.001
Night (7 pm-6:59 am)	139 (43.0)	32 (29.4)	107 (50.0)	
Witnessed				
No	2 (0.6)	1 (0.9)	1 (0.5)	0.62
Yes	321 (99.4)	108 (99.1)	213 (99.5)	
Previous interventions				
Mechanical ventilation				
No	88 (27.2)	43 (39.4)	45 (21.0)	0.002
Yes	232 (71.8)	65 (59.6)	167 (78.0)	
Unknown	3 (0.9)	1 (0.9)	2 (0.9)	
Vasoactive drugs				
No	168 (52.0)	90 (82.6)	78 (36.4)	<0.001
Yes	152 (47.1)	18 (16.5)	134 (62.6)	
Unknown	3 (0.9)	1 (0.9)	2 (0.9)	
Immediate cause				
Respiratory	153 (47.4)	78 (71.6)	75 (35.0)	<0.001
Shock	121 (37.5)	10 (9.2)	111 (51.9)	
Metabolic	32 (9.9)	9 (8.3)	23 (10.7)	
Arrhythmia	8 (2.5)	5 (4.6)	3 (1.4)	
Unknown	9 (2.8)	7 (6.4)	2 (0.9)	
Rhythm				
Bradycardia	181 (56.0)	69 (63.3)	112 (52.3)	0.16
PEA	77 (23.8)	24 (22.0)	53 (24.8)	
Asystole	49 (15.2)	10 (9.2)	39 (18.2)	
VT/VF	10 (3.1)	3 (2.8)	7 (3.3)	
Unknown	6 (1.9)	3 (2.8)	3 (1.4)	
CPR duration			()	
Up to 5 min	130 (40.2)	65 (59.6)	65 (30.4)	<0.001
>5-15 min	87 (26.9)	28 (25.7)	59 (27.6)	
>15-30 min	61 (18.9)	12 (11)	49 (22.9)	
>30 min	42 (13.0)	3 (2.8)	39 (18.2)	
Unknown	3 (0.9)	1 (0.9)	2 (0.9)	
Epinephrine	00 (11 0)			0.004
No	38 (11.8)	25 (22.9)	13 (6.1)	<0.001
Yes	285 (88.2)	84 (77.1)	201 (93.9)	
Bicardonate	100 (57.0)	00 (01 7)	07 (45.2)	-0.004
		09 (10 0)	97 (45.3)	<0.001
res Coloium	137 (42.4)	20 (18.3)	117 (54.7)	
Valcium No.	006 (70.0)	01 (02 5)	105 (60.1)	-0.001
NO	220 (70.0)	91 (83.5)	133 (b3.1) 70 (26.0)	<0.001
Yes	97 (30.0)	18 (16.5)	79 (30.9)	

Subtitles PICU, paediatric intensive care unit; OR, operating room; PEA, pulseless electrical activity; VT, pulseless ventricular taquicardia; VF, ventricular fibrilation; CPR, cardiopulmonary resuscitation. Significant values in bold.

diac arrest cause, CPR duration, and drugs given during CPR (adrenaline, bicarbonate, and calcium).

Patients <1 year old (59.7%) constituted the dominant population. Nearly the entire sample (96.3%) had a complex chronic conditions, the most frequent being prenatal conditions and complications (25.7%) and liver diseases (23.8%), followed by genetic-metabolic diseases (18.3%) and onco-hematologic and immunological diseases (8.4%).

The intensive care unit (ICU) was the location with the highest number of CPR occurrences (80.2%), followed by those in the emergency room (9%), operating room (7.7%), and wards (3.1%). CPR

events were proportionally similar between weekdays and weekends, and 57% were during the daytime period.

Of the interventions in place prior to CPR, it is noteworthy that most patients (71.8%) were under mechanical ventilation and nearly half (47.1%) were on vasoactive drug support, reflecting the severity of the patient's condition. The primary immediate causes were respiratory (47.4%) and shock-related (37.5%), followed by metabolic (9.9%) and arrhythmias (2.5%).

Bradycardia, pulseless electrical activity, and asystole were the most frequent initial rhythms, and the presence of shockable rhythms was rare (3.1%). Short-duration CPR (up to 15 minutes) occurred in

# Table 2 - Regression analysis for characteristics associated with survival to hospital discharge.

Characteristics	Univariate			Multivariat	e	
	OR	CI (95%)	P-value	OR	CI (95%)	P-value
Age group						
<1 month	0.477	[0.252; 0.901]	0.02	0.954	[0.349; 2.609]	0.92
≥1 month-<1 year	1.000	-	-	1.000	-	-
$\geq$ 1 year-<12 years	0.671	[0.389; 1.155]	0.15	0.997	[0.421; 2.361]	0.99
$\geq$ 12 years old	0.383	[0.133; 1.102]	0.07	0.341	[0.068; 1.724]	0.19
Sex						
Female	1.000	-	-			
Male	0.730	[0.459; 1.161]	0.18			
Complex chronic conditions						
No	1.000	-	-			
Yes	0.240	[0.071; 0.817]	0.02			
Disease categories						
Absent	1.000	-	-	1.000	-	-
Hepatic	0.111	[0.029; 0.421]	0.001	0.060	[0.007; 0.510]	0.010
Prenatal condition or complications	0.228	[0.063; 0.826]	0.02	0.248	[0.030; 2.036]	0.19
Other	0.429	[0.117; 1.566]	0.20	0.119	[0.015; 0.933]	0.04
Oncohematologic or immunologic	0.294	[0.070; 1.232]	0.09	0.288	[0.031; 2.632]	0.27
Genetic or metabolic	0.276	[0.074; 1.027]	0.05	0.134	[0.016; 1.190]	0.06
Event location						
PICU	1.000	-	-	1.000	-	-
Wards	3.545	[0.973; 12.917]	0.05	2.094	[0.229; 19.134]	0.51
Emergency department	1.444	[0.652; 3.202]	0.36	0.796	[0.232; 2.737]	0.71
OR/Endoscopy/Diagnostic area	3.545	[1.525; 8.240]	0.003	18.977	[3.832; 93.976]	<0.001
Period of the week	4 000					
Weekday	1.000	-	-			
Weekend	0.804	[0.472; 1.369]	0.42			
Period of the day	1 000			1 000		
Day (7 n-18 n59)	1.000		-	1.000	-	-
Night (7 pm–6.59am)	0.416	[0.254; 0.679]	<0.001	0.890	[0.418; 1.894]	0.76
Previous interventions						
	1 000			1 000		
NO	1.000	-	-	0.701	-	- 0.40
Yesestive druge	0.407	[0.245, 0.676]	0.001	0.721	[0.322, 1.010]	0.42
No	1 000			1 000		
Voc	0.116	-	-0.001	0.145	-	-0.001
Immediate aquee	0.110	[0.005, 0.207]	<0.001	0.145	[0.005, 0.525]	<0.001
Respiratory	1 000	_	_	1 000	_	_
Shock/hypotension	0.087	- [0 0/2: 0 178]	~0.001	0.183	[0 060: 0 486]	0.001
Metabolic/Arrbythmia/Sudden/Unknown	0.721	[0.377: 1.379]	0.32	1 739	[0.632: 4.784]	0.28
Bhythm	0.721	[0.077, 1.070]	0.02	1.700	[0.002, 4.704]	0.20
Bradycardia	1 000	_	_	1 000	_	_
Assistolia	0.416	[0 195 0 887]	0.02	0.911	[0.310 2.682]	0.86
PFA	0.735	[0.417: 1.297]	0.28	1 393	[0.567: 3.422]	0.00
VT/VE	0.696	[0 174: 2 780]	0.60	0.391	[0.044: 3.474]	0.39
Unknown	1 623	[0.319: 8.269]	0.56	0.781	[0.051: 12.050]	0.85
CPB duration	1.020	[0.010, 0.200]	0.00	0.701	[0.001, 12.000]	0.00
Up to 5 min	1 000	-	-	1 000	-	-
>5–15 min	0.475	[0.269: 0.836]	0.010	0.807	[0.353: 1.845]	0.61
>15-30 min	0.245	[0 119: 0 503]	<0.001	0.317	[0.106: 0.950]	0.04
>30 min	0.077	[0.023: 0.261]	<0.001	0.070	[0.014: 0.344]	0.001
Epinephrine		[3, 001]		5.0.0	[	
No	1.000	_	_	1.000	_	_
Yes	0.217	[0.106: 0.445]	<0.001	0.517	[0,171; 1,561]	0.24
Bicarbonate		[			[	
No	1.000	-	-	1.000	-	-
Yes	0.186	[0.107; 0.324]	<0.001	0.318	[0.130; 0.780]	0.01
Calcium		. , = .]			,	
No	1.000	-	-	1.000	-	-
Yes	0.338	[0.190; 0.602]	<0.001	1.022	[0.403; 2.589]	0.96
	i' DIOLL	. ,	1 OD			

95% CI indicates 95% confidence interval; OR, odds ratio; PICU, paediatric intensive care unit; OR; operating room; PEA, pulseless electrical activity; VT, pulseless ventricular tachycardia; VF, ventricular fibrillation. Significant values in bold.

# Table 3 - Regression analysis for characteristics associated with survival at 180 days.

Age group        	Characteristics	Univariate			Multivariat	e	
Age group		OR	CI (95%)	P-value	OR	CI (95%)	P-value
<1         month         0.612         [0.314, 1.192]         0.14         1.603         [0.57, 4.474]         0.36           ≥1 month-1year         0.928         [0.527, 1.53]         0.79         1.588         [0.669, 3.789]         0.29           ≥1 year-S12 years         0.928         [0.577, 1.63]         0.79         1.588         [0.669, 3.789]         0.29           Sex                  Fernale         1.000         -         -         1.000         -         -         -         -         -           No         1.000         -	Age group						
≥1         month—1 years         1.000         -         -         1.000         -	<1 month	0.612	[0.314; 1.192]	0.14	1.603	[0.574; 4.474]	0.36
≥1 year-s12 years         0.528         (0.527, 1.632)         0.79         1.588         [0.662, 3.769]         0.29           Sex           Female         1.000         -         -         1.000         0.77         0.135, 3130]         0.99           General         0.010         -         -         1.000         -         -         -           Male         0.010         -	$\geq$ 1 month–<1 year	1.000	-	_	1.000	-	-
≥ 2 years old         0.570         [0.197; 1.652]         0.30         0.651         [0.135; 3; 130]         0.59           Sex         -         -         1.000         -         -         1.000         -         -         -           Male         0.010         [0.374; 0.995]         0.04         0.554         [0.280; 1.097]         0.09           Complex chronic conditions         -         0.007         0.007         0.007         0.007         0.007         0.007         -         -         -         -         -         -         -         -         -         -         -         -         - <td><math>\geq</math>1 year–&lt;12 years</td> <td>0.928</td> <td>[0.527; 1.633]</td> <td>0.79</td> <td>1.588</td> <td>[0.669; 3.769]</td> <td>0.29</td>	$\geq$ 1 year–<12 years	0.928	[0.527; 1.633]	0.79	1.588	[0.669; 3.769]	0.29
Six         -         -         1.000         - </td <td><math>\geq</math>12 years old</td> <td>0.570</td> <td>[0.197; 1.652]</td> <td>0.30</td> <td>0.651</td> <td>[0.135; 3.130]</td> <td>0.59</td>	$\geq$ 12 years old	0.570	[0.197; 1.652]	0.30	0.651	[0.135; 3.130]	0.59
Female         1.000         -         -         1.000         -         Derises actaporis actaport actaport actaport acta	Sex						
Male         0.610         [0.374; 0.995]         0.04         0.554         [0.280; 1.097]         0.09           No         1.000         - <td< td=""><td>Female</td><td>1.000</td><td>-</td><td>-</td><td>1.000</td><td>-</td><td>-</td></td<>	Female	1.000	-	-	1.000	-	-
Complex chronic conditions	Male	0.610	[0.374; 0.995]	0.04	0.554	[0.280; 1.097]	0.09
No         1.000         - </td <td>Complex chronic conditions</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Complex chronic conditions						
Yes         0.221         [0.063; 0.775]         0.01         -	No	1.000	-	-	-	-	-
Disease categories No 1000 1000 0000 - 0.000 - 0.0000 - 0.0000 0.0000, 0.693 0.02 Prenatal condition or complications 0.178 [0.047, 0.674] 0.011 0.159 [0.016; 1.534] 0.111 Other 0.406 [0.108; 1.526] 0.18 0.129 [0.013; 1.120] 0.06 Oncohematologic or immunologic 0.336 [0.0078; 1.441] 0.14 0.310 [0.030; 3.220] 0.322 Genetic or metabolic 0.251 [0.065; 0.965] 0.04 0.131 [0.014; 1.266] 0.07 Event location PICU 1.000 1.000 1.000 PICU 1.000 [0.52; 4.246] 0.11 1.291 [0.388; 4.530] 0.692 OR/Endoscopy/Diagnostic area 3.962 [1.711; 9.176] 0.011 1.858 [2.540; 55.349] 0.092 Period of the week Weekday 0.020 [0.531; 1.533] 0.76 Period of the week Weekday 0.020 [0.531; 1.533] 0.76 Period of the day Day (2 m - 6.59 pm) 0.416 [0.248; 0.699] 0.010 0.782 [0.355; 1.635] 0.48 Previous interventions Weeknad 0.920 [0.576; 1.241] 0.008 1.037 [0.464; 2.317] 0.93 Vasaactive drugs No 1.000 1.000 0.000 Vees 0.492 [0.292; 0.811] 0.008 1.037 [0.464; 2.317] 0.93 Vasaactive drugs No 1.000 Yees 0.492 [0.292; 0.81] 0.008 1.037 [0.464; 2.317] 0.93 Vasaactive drugs No 1.000 Night (7 pm -6.59 pm) 0.048 [0.040; 0.194] <0.011 0.183 [0.57; 0.472] 0.001 Immediate cause Thereination 0.088 [0.040; 0.194] <0.001 0.183 [0.57; 0.472] 0.001 Matabolic/Arrhythmia/Sudden/Unknow 0.848 [0.248; 0.693] 0.025 1.035 1.034 [0.402; 2.411] 0.43 Prenation 0.084 [0.075; 0.249] <0.283 1.037 1.271 [0.470; 3.436] 0.53 Unknown 0.345 [0.219; 3.420] 0.35 1.034 [0.429; 2.491] 0.40 PEA 0.756 [0.419; 1.365] 0.35 1.034 [0.429; 2.491] 0.40 PEA 0.756 [0.219; 0.493 0.35 Unknown 0.331 [0.161; 0.682] 0.003 0.51 1.043 [0.577; 0.472] 0.001 Matabolic/Arrhythmia/Sudden/Unknow 0.384 [0.219; 0.429] 0.03 0.35 1.034 [0.429; 2.491] 0.40 PEA 0.756 [0.219; 0.429] 0.03 0.51 0.345 [0.037; 0.320] 0.35 Unknown 0.331 [0.161; 0.682] 0.003 0.51 0.345 [0.37; 0.240] 0.35 Unknown 0.331 [0.161; 0.682] 0.003 0.51 0.345 [0.377] 0.40 PEA 0.756 [0.219; 0.420] 0.03 0.513 0.35 0.35 Unknown 0.331 [0.161; 0.682] 0.003 0.51 0.437	Yes	0.221	[0.063; 0.775]	0.01	-	-	-
No         1.000         −         −         1.000         −         −           Hepatic         0.105         [0.027; 0.471]         0.011         0.1070         [0.007; 0.693]         0.02           Prenatal condition or complications         0.178         [0.047; 0.674]         0.011         0.152         [0.015; 1.120]         0.066           Oncohematologic         0.326         [0.078; 1.441]         0.14         0.310         [0.041; 1.266]         0.078           Genetic or metabolic         0.251         [0.065; 0.965]         0.04         0.131         [0.014; 1.266]         0.07           Wards         4.669         [1.276; 17.084]         0.02         4.550         [0.474; 43.628]         0.18           Emergency department         1.900         -         -         -         1.000         -         -           Weekday         1.000         -         -         1.000         -         -         -           Weekday         0.001         -         -         1.000         -         -         -           Weekday         0.001         -         -         1.000         -         -         -         0.002           Vesckondy         0.000	Disease categories						
Hepatic         0.105         (0.027, 0.477)         0.001         0.007, 0.693         0.02           Prenatal condition or complications         0.178         (0.047, 0.674)         0.011         0.159         (0.016, 1.534)         0.011           Orhor         0.406         [0.108, 1.526]         0.18         0.122         [0.013; 1.120]         0.06           Genetic or metabolic         0.251         [0.065; 0.965]         0.04         0.131         [0.014; 1.266]         0.07           Event location         -         1.000         -         -         1.000         -         -         -           Wards         4.669         [1.711; 9.176]         0.021         4.550         [0.474; 43.628]         0.18           Emergency department         1.902         [0.852; 4.246]         0.111         1.281         [0.368; 4.530]         0.69           ORREndoscopy/Diagnesic area         3.982         [1.711; 9.176]         0.001         1.888         [2.540; 55.349]         0.002           Perid of the week         .020         [5.51; 1.533]         0.76         -         -         -         No         -         -         No         -         -         -         No         -         -         -	No	1.000	-	-	1.000	-	-
Prinatal condition or complications         0.178         (0.047, 0.074, 1         0.01         0.152         [0.016; 1.324]         0.11           Other         0.0466         [0.108; 1.526]         0.18         [0.03; 3.220]         0.32           Genetic or immunologic         0.336         [0.078; 1.441]         0.14         0.310         [0.014; 1.266]         0.07           Event location           0.045; 0.965         0.044         0.031         [0.038; 4.530]         0.69           Wards         4.669         [1.276; 17.084]         0.002         4.550         [0.474; 43.628]         0.69           OR/Endoscopy/Diagnostic area         3.962         [1.711; 9.176]         0.001         1.858         [2.540; 55.349]         0.002           Perid of the week                  Weekady         1.000         -         -          1.000	Hepatic	0.105	[0.027; 0.417]	0.001	0.070	[0.007; 0.693]	0.02
Other         0.146         [0.108]         1.526         0.18         0.132         [0.013]         1.201         0.036         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.036]         3.222         [0.014]         1.266]         0.037         2.221         [0.036]         3.232         [0.077]         2.211         [0.036]         3.230         0.76           Wards         4.669         1.276         7.048         0.021         0.76         -         <	Prenatal condition or complications	0.178	[0.047; 0.674]	0.01	0.159	[0.016; 1.534]	0.11
Oncohematologic         0.38         [0.078; 1.441]         0.14         0.131         [0.036; 3.220]         0.32           Event location         0.251         [0.065; 0.965]         0.04         0.131         [0.014; 1.266]         0.07           Wards         4.669         [1.276; 17.084]         0.02         4.550         [0.474; 4.3628]         0.18           Emergency department         1.902         [0.852; 4.246]         0.101         1.281         [0.368; 4.530]         0.692           ORE:ndoscopy/Diagnostic area         3.982         [1.711; 9.176]         0.001         1.858         [2.540; 55.349]         0.002           Weekday         1.000         -         -         1.000         -         -         1.001         -         -         -         1.002         -         -         1.002         -         -         -         1.002         -	Other	0.406	[0.108; 1.526]	0.18	0.122	[0.013; 1.120]	0.06
Genetic or metabolic         0.251         (0.065; 0.965)         0.04         0.131         (0.013; 1.266)         0.07           Pictu         1.000         -         -         1.000         -         0.002         Period of the week         -         -         1.000         -         -         -         -         -         -         No         1.000         -         -         -         1.000         - <td< td=""><td>Oncohematologic or immunologic</td><td>0.336</td><td>[0.078; 1.441]</td><td>0.14</td><td>0.310</td><td>[0.030; 3.220]</td><td>0.32</td></td<>	Oncohematologic or immunologic	0.336	[0.078; 1.441]	0.14	0.310	[0.030; 3.220]	0.32
Event location PICU 1.000	Genetic or metabolic	0.251	[0.065; 0.965]	0.04	0.131	[0.014; 1.266]	0.07
PICO         1.000         -         -         -         1.000         - <t< td=""><td>Event location</td><td>1 000</td><td></td><td></td><td>4 000</td><td></td><td></td></t<>	Event location	1 000			4 000		
Wards         4.669         [1.276] (7.064]         0.02         4.550         [0.474] (4.3.628]         0.18           Emergency department         1.902         [0.852] (4.246]         0.11         1.291         [0.368] (4.530]         0.69           OR/Endoscopy/Diagnostic area         3.962         [1.711; 9.176]         0.001         11.858         [2.540; 55.349]         0.002           Period of the week         0.920         [0.531; 1.533]         0.76         -         -           Weekday         1.000         -         -         -         -         -           Period of the day         -         -         1.000         -         -         -         -         -         -           Night (7 pm - 6:59 am)         0.416         [0.248; 0.699]         0.001         0.762         [0.355; 1.635]         0.48           Previous interventions         -         -         1.000         - <t< td=""><td>PICU</td><td>1.000</td><td>-</td><td>-</td><td>1.000</td><td>-</td><td>-</td></t<>	PICU	1.000	-	-	1.000	-	-
Emergency department         1.902         [0.82; 4.246]         0.11         1.291         [0.363; 4.353]         0.092           Period of the week         U         U         0.001         1.858         [2.540; 55:349]         0.002           Weekday         0.000         -         -         -         -         -           Weekend         0.920         [0.531; 1.593]         0.76         -         -         -           Day (7 am - 6:59 pm)         0.416         [0.248; 0.699]         0.001         -         -         -         -           No         1.000         -         -         1.000         -	wards	4.669	[1.276; 17.084]	0.02	4.550		0.18
Orientoscopy/Diagnostic area         3.962         [1,71,19,176]         0.001         11.858         [2.940; 55.349]         0.002           Period of the week	Emergency department	1.902	[0.852; 4.246]	0.11	1.291	[0.368; 4.530]	0.69
Period of the Week         Ine Week <td>OR/Endoscopy/Diagnostic area</td> <td>3.962</td> <td>[1.711; 9.176]</td> <td>0.001</td> <td>11.858</td> <td>[2.540; 55.349]</td> <td>0.002</td>	OR/Endoscopy/Diagnostic area	3.962	[1.711; 9.176]	0.001	11.858	[2.540; 55.349]	0.002
Weekend         0.000         -         -           Period of the day         -         -         1.000         -         -         1.000         -         -         -         Nob         -         -         -         -         Nob         -         -         -         Nob         -         -         -         -         Nob         -         -         -         -         -         Nob         -         -         -         -         -         -         -         Nob         1.000         -         <	Period of the week	1 000					
Weeken of the day         Units of the day           Day (7 am - 6:59 pm)         1.000         -         -         1.000         -         -           Night (7 pm - 6:59 am)         0.416         [0.248; 0.699]         0.001         0.762         [0.355; 1.635]         0.480           Previous interventions         -         -         1.000         -         -         -           No         1.000         -         -         1.000         -         -           Yes         0.492         [0.292; 0.831]         0.008         1.037         [0.464; 2.317]         0.93           Vasoactive drugs         -         -         1.000         -         -         -         -         -         0.001         0.192         [0.085; 0.437]         <0.001	Weekaay	1.000		-			
Period of the day           Day (7 am - 6:59 am)         0.416         [0.248; 0.699]         0.001         0.762         [0.355; 1.635]         0.48           Previous interventions	Weekend	0.920	[0.531; 1.593]	0.76			
Day (Value - 0.59 pm)         1.000         -         -         1.000         -         -         -         1.000         -	Dov (Z om 6:50 pm)	1 000			1 000		
Night (* pin – 6.39 and)         0.416         (0.246, 0.639)         0.001         0.762         (0.353, 1.635)         0.465           Mechanical ventilation	Day (7 am $-$ 0.59 pm)	1.000	-	-	1.000		- 0.49
Previous interventions           No         1.000         -         -         1.000         -         -           No         1.000         -         -         1.000         -         -           Yes         0.492         [0.292; 0.831]         0.008         1.037         [0.46; 2.317]         0.93           Vasoactive drugs         -	Reviews interventions	0.416	[0.248; 0.699]	0.001	0.762	[0.355; 1.635]	0.48
No         1.000         -         -         1.000         -         -         -           Yes         0.492         [0.292; 0.831]         0.008         1.037         [0.464; 2.317]         0.93           Vasoactive drugs         . <td< td=""><td>Mechanical ventilation</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Mechanical ventilation						
NO         1.000         -         -         1.000         -         -           Yes         0.492         [0.292; 0.831]         0.008         1.037         [0.464; 2.317]         0.93           Vasoactive drugs         .         -         -         -         -         -           Yes         0.136         [0.75; 0.249]         <0.001	No	1 000			1 000		
Toss         0.492         [0.507]         (0.607)         [0.407]         (0.407)         (0.417)         (0.416)         (0.416)         (0.416)         (0.416)         (0.416)         (0.416)         (0.416)         (0.416)         (0.416)         (0.416)         (0.417)         (0.416)         (0.	Vec	0.492	-	0.008	1.000	-	-
No         1.000         -         -           Yes         0.136         [0.075; 0.249]         <0.001	Vasoactive drugs	0.432	[0.232, 0.001]	0.000	1.007	[0.404, 2.017]	0.95
No         1.000         -         -         0.136         [0.075; 0.249]         <0.001         0.192         [0.085; 0.437]         <0.001           Immediate cause         -         -         1.000         - <td< td=""><td>No</td><td>1 000</td><td>_</td><td>_</td><td></td><td></td><td></td></td<>	No	1 000	_	_			
Integration         Integration <thintegration< th=""> <thintegration< th=""></thintegration<></thintegration<>	Ves	0.136	[0 075: 0 249]	<0.001	0 192	[0.085: 0.437]	<0.001
Ministration         1.000         -         -         1.000         -	Immediate cause	0.100	[0.070, 0.240]	20.001	0.102	[0.000, 0.407]	<0.001
Noop         Noo         No         Noo         Noo         Noo <td>Bespiratory</td> <td>1 000</td> <td>_</td> <td>_</td> <td>1 000</td> <td>-</td> <td>_</td>	Bespiratory	1 000	_	_	1 000	-	_
Bitson (P) outside         Disconsistion         Disconsis <thdisconsistion< th="">         Disconsi</thdisconsistion<>	Shock/hypotension	0.088	[0 040 <sup>,</sup> 0 194]	<0.001	0 163	[0 057: 0 472]	0.001
Rhythm         Instrume         [biblic]         biblic]         biblic]         [biblic]         [biblic] <th< td=""><td>Metabolic/Arrhythmia/Sudden/Unknown</td><td>0.000</td><td>[0.370: 1.397]</td><td>0.33</td><td>1 271</td><td>[0.470: 3.436]</td><td>0.63</td></th<>	Metabolic/Arrhythmia/Sudden/Unknown	0.000	[0.370: 1.397]	0.33	1 271	[0.470: 3.436]	0.63
Bradycardia         1.000         -         -         1.000         -         -           Assistolia         0.394         [0.173; 0.893]         0.02         0.628         [0.210; 1.879]         0.40           PEA         0.756         [0.419; 1.365]         0.35         1.034         [0.429; 2.491]         0.94           TV/FV         0.864         [0.216; 3.464]         0.83         0.345         [0.037; 3.250]         0.35           Unknown         1.345         [0.219; 8.267]         0.74         0.787         [0.031; 19.699]         0.88           CPR duration          -         -         1.000         - <td>Bhythm</td> <td>011 10</td> <td></td> <td>0.00</td> <td></td> <td>[01110, 01100]</td> <td>0.00</td>	Bhythm	011 10		0.00		[01110, 01100]	0.00
Assistolia         0.394         [0.173; 0.893]         0.02         0.628         [0.210; 1.879]         0.40           PEA         0.756         [0.419; 1.365]         0.35         1.034         [0.429; 2.491]         0.94           TV/FV         0.864         [0.216; 3.464]         0.83         0.345         [0.037; 3.250]         0.35           Unknown         1.345         [0.219; 8.267]         0.74         0.787         [0.031; 19.699]         0.88           CPR duration            -         1.000         -         -         -           Up to 5 min         1.000         -         -         1.000         -         -         -           >5-15 min         0.523         [0.291; 0.942]         0.03         0.978         [0.431; 2.217]         0.95           >15-30 min         0.523         [0.292] <b>0.003</b> 0.513         [0.167; 1.571]         0.24           >30 min         0.068         [0.016; 0.292] <b>0.001</b> 0.048         [0.007; 0.340]         0.002           Epinephrine                 0.20           Bicarbonate	Bradycardia	1.000	-	_	1.000	_	_
PEA         0.756         [0.419; 1.365]         0.35         1.034         [0.429; 2.491]         0.94           TV/FV         0.864         [0.216; 3.464]         0.83         0.345         [0.037; 3.250]         0.35           Unknown         1.345         [0.219; 8.267]         0.74         0.787         [0.031; 19.699]         0.88           CPR duration	Assistolia	0.394	[0.173: 0.893]	0.02	0.628	[0.210: 1.879]	0.40
TV/FV         0.864         [0.216; 3.464]         0.83         0.345         [0.037; 3.250]         0.35           Unknown         1.345         [0.219; 8.267]         0.74         0.787         [0.037; 3.250]         0.38           CPR duration         Up to 5 min         1.000         -         -         1.000         -         -           >5-15 min         0.523         [0.291; 0.942]         0.03         0.978         [0.431; 2.217]         0.95           >15-30 min         0.331         [0.161; 0.682]         0.003         0.513         [0.167; 1.571]         0.24           >30 min         0.068         [0.016; 0.292]         <0.001	PEA	0.756	[0.419: 1.365]	0.35	1.034	[0.429; 2.491]	0.94
Unknown         1.345         [0.219; 8.267]         0.74         0.787         [0.031; 19.69]         0.88           CPR duration         Up to 5 min         1.000         -         -         1.000         -         -           >5–15 min         0.523         [0.291; 0.942]         0.03         0.978         [0.431; 2.217]         0.95           >15–30 min         0.331         [0.161; 0.682]         0.003         0.513         [0.167; 1.571]         0.24           >30 min         0.068         [0.016; 0.292]         <0.001         0.048         [0.007; 0.340]         0.002           Epinephrine         U         U         U         U         U         U         U           No         1.000         -         -         1.000         -         -         -           Yes         0.229         [0.113; 0.466]         <0.001         0.502         [0.175; 1.445]         0.20           Bicarbonate         U         U         U         -         -         1.000         -         -           No         1.000         -         -         1.000         -         -         -         -           Yes         0.372         [0.203; 0.680] <td>TV/FV</td> <td>0.864</td> <td>[0.216: 3.464]</td> <td>0.83</td> <td>0.345</td> <td>[0.037: 3.250]</td> <td>0.35</td>	TV/FV	0.864	[0.216: 3.464]	0.83	0.345	[0.037: 3.250]	0.35
CPR duration       1.000       -       -       1.000       -       -         >5-15 min       0.523       [0.291; 0.942]       0.03       0.978       [0.431; 2.217]       0.95         >15-30 min       0.331       [0.161; 0.682]       0.003       0.513       [0.167; 1.571]       0.24         >30 min       0.068       [0.016; 0.292]       <0.001	Unknown	1.345	[0.219: 8.267]	0.74	0.787	[0.031: 19.699]	0.88
Up to 5 min         1.000         -         -         1.000         -	CPR duration		[,]			[]	
>5-15 min       0.523       [0.291; 0.942]       0.03       0.978       [0.431; 2.217]       0.95         >15-30 min       0.331       [0.161; 0.682]       0.003       0.513       [0.167; 1.571]       0.24         >30 min       0.068       [0.016; 0.292]       <0.001	Up to 5 min	1.000	-	-	1.000	-	-
>15–30 min       0.331       [0.161; 0.682]       0.003       0.513       [0.167; 1.571]       0.24         >30 min       0.068       [0.016; 0.292]       <0.001	>5–15 min	0.523	[0.291; 0.942]	0.03	0.978	[0.431; 2.217]	0.95
>30 min         0.068         [0.016; 0.292]         <0.001         0.048         [0.007; 0.340]         0.002           Epinephrine	>15–30 min	0.331	[0.161; 0.682]	0.003	0.513	[0.167; 1.571]	0.24
Epinephrine         –         1.000         –         –         1.000         –         –         –         1.000         –	>30 min	0.068	[0.016; 0.292]	<0.001	0.048	[0.007; 0.340]	0.002
No         1.000         -         -         1.000         -	Epinephrine		. , .				
Yes         0.229         [0.113; 0.466]         <0.001         0.502         [0.175; 1.445]         0.20           Bicarbonate         No         1.000         -         -         1.000         -         -         -           Yes         0.198         [0.110; 0.355]         <0.001	No	1.000	-	-	1.000	-	-
Bicarbonate         -         1.000         -	Yes	0.229	[0.113; 0.466]	<0.001	0.502	[0.175; 1.445]	0.20
No         1.000         -         -         1.000         -         -           Yes         0.198         [0.110; 0.355]         <0.001	Bicarbonate		· · ·				
Yes0.198[0.110; 0.355]<0.0010.347[0.138; 0.870]0.02CalciumNo1.0001.000Yes0.372[0.203; 0.680]0.0011.285[0.503; 3.280]0.60	No	1.000	-	-	1.000	-	-
Calcium         -         1.000         -         -         1.000         -	Yes	0.198	[0.110; 0.355]	<0.001	0.347	[0.138; 0.870]	0.02
No         1.000         -         -         1.000         -	Calcium					-	
Yes 0.372 [0.203; 0.680] <b>0.001</b> 1.285 [0.503; 3.280] 0.60	No	1.000	-	-	1.000	-	-
	Yes	0.372	[0.203; 0.680]	0.001	1.285	[0.503; 3.280]	0.60

95% CI indicates 95% confidence interval; OR, odds ratio; PICU, paediatric intensive care unit; OR, operating room; PEA, pulseless electrical activity; VT, pulseless ventricular tachycardia; VF, ventricular fibrillation. Significant values in bold.

Adrenaline was used in the vast majority (88.2%) of patients. Bicarbonate and calcium, which are not routinely recommended by CPR guidelines, were used in 42.4% and 30% of patients, respectively.

#### Factors associated with survival to discharge

Table 2 presents the univariable analysis. The following factors were significantly associated with lower survival to discharge: age <1 month; liver disease; prenatal conditions and complications; occurrence at night;, interventions prior to CPR;, shock as the immediate cause; asystole as the initial rhythm; CPR duration >5 minutes; and use of adrenaline, bicarbonate, or calcium during CPR.

Multivariable analysis (Table 2) found lower survival to discharge to be significantly associated with pre-existing liver disease, vasoactive drug support before cardiac arrest, shock as the immediate cause, CPR prolonged duration, and use of bicarbonate during CPR.

#### Factors associated with survival after 180 days

Table 3 shows the factors associated with survival after 180 days found in univariable analysis. Male sex; liver disease; genetic and metabolic disease; prenatal conditions or complications; occurrence at night; interventions in place at time of event (mechanical ventilation and vasoactive drug infusion); shock as the immediate cause; asystole as initial rhythm; CPR duration >5 minutes; and use of adrenaline, bicarbonate, or calcium during CPR were significantly associated with lower survival after 180 days. Multivariable analysis identified following variables significantly associated with lower survival after 180 days. Pre-existing liver disease, vasoactive drug support before cardiac arrest, shock as the immediate cause, CPR prolonged duration, and use of bicarbonate during CPR.

#### Neurological outcome

Table 4 and Fig. 1 shows the neurological outcome in the 93 survivors after 180 days. Approximately-one-third already presented prearrest neurological dysfunction. Between the prearrest and discharge period, 20.2% of patients had an unfavourable prognosis. Neurological outcome was similar between discharge and after 180 days. Twenty-three patients with severe dysfunction prearrest (Paediatric Cerebral Performance Category 4) remained stable after 180 days. Neurological outcome was mostly favourable at discharge (79.7%) and after 180 days (76.1%).

Univariable and multivariable analysis was conducted to evaluate factors associated with good neurological prognosis was carried out in the 93 survivors after 180 days. In multivariable analysis, factors associated with favourable neurological prognosis age >1 year

(OR: 23.894, 95%CI 2.735–208.735, p = 0.004) and non-administration of vasoactive drugs pre-CPR (OR: 4.518, 95%CI 1.116–18.291, p = 0.03) (Supplemental Table 1).

#### Discussion

This study analysed the association of a set of factors with paediatric CPR survival in patients with complex chronic conditions in a highcomplexity hospital. Prior liver disease, vasoactive drug support before CA, shock as the immediate cause, prolonged CPR, and use of bicarbonate were significantly associated with lower survival both at discharge and after 180 days. Most patients had a favourable neurological prognosis at discharge and after 180 days.

This study is characterized by a robust sample of patients with complex chronic conditions (96.3%) in a middle-income country, where literature data are scarce. Patients with complex chronic conditions have a higher frequency of hospitalization,<sup>17</sup> which is related with life expectancy currently increasing, likely as result of early diagnosis and technological advances, especially in cardiorespiratory support. This population should be highlighted in studies on inhospital CPR from now on.

Paediatric in-hospital CPR outcomes greatly vary according to different services and between countries (Table 5). Inequality in cardiac arrest care, which depends on training, expertise, human resources, equipment, ICU beds, and multidisciplinary team along with the variability in human development indexes may explain the different outcomes.

However, rates of survival to discharge (33.7%) and after 180 days (29.2%) as shown in this study are aligned with the literature from high-income countries (Table 5). Additionally, there was an overall improvement in survival when comparing a similar study previously conducted in the same hospital with the current data (ROSC from 64% to 70.9%; survival to discharge 16.3–33.7%; survival after 180 days 15.5–29.2%, respectively).<sup>3</sup>

In-hospital paediatric cardiac arrest typically occurs in patients with pre-existing diseases, who account for 71.0% to 90.9% of cases.<sup>3–5,20,31–33</sup> In the present study, 96.3% of patients had complex chronic conditions, reinforcing the literature findings on the increased prevalence in this population.<sup>17</sup> The prognosis of cardiac arrest appears to be influenced by the complex chronic conditions category, and thus further studies must address this issue.

Liver disease was the most frequent condition noted in the current study, having been associated with lower rates of survival to discharge and after 180 days. Previous studies in the same hospital have already reported liver disease as the most common condition.<sup>3,34</sup> These findings can be attributed to the fact that the hospital

Table 4 – Neu	rological outco	ome.				
PCPC	Pre-arrest N %		Hospital Dis N %	charge	180 days N %	
1	56	60.2%	31	33.3%	30	32.3%
2	7	7.5%	15	16.1%	11	11.8%
3	5	5.4%	5	5.4%	8	8.6%
4	23	24.7%	41	44.1%	41	44.1%
Unknown	2	2.2%	1	1.1%	3	3.2%
Total	93	100.0%	93	100.0%	93	100.0%
PCPC, pediatric cere	bral performance ca	tegories; N, number of p	atients.			

Author	Country	Year	Study Type	Ν	Setting	ROSC (%)	Survival to discharge (%)	Good neurological survival (%)	6 months or 1 year survival (%)
Slonin <sup>48</sup>	USA	1997	Prospective	205	PICU	UNK	13.7	UNK	UNK
Suominen <sup>24</sup>	Finland	2000	Retrospective	118	In-hospital	62.7	19.5	12.7	17.8
Reis <sup>3</sup>	Brazil	2002	Prospective	129	In-hospital	64	16.2	89.5	14.7
Guay <sup>49</sup>	Canada	2004	Retrospective	203	In-hospital	73.8	40.8	23.4	26
Rodriguez-Nuñes <sup>50</sup>	Spain	2006	Prospective	116	PICU	59.5	35.3	31	34.5
Tibballs <sup>19</sup>	Australia	2006	Prospective	111	In-hospital	76	36	UNK	34
Nadkarni <sup>1</sup>	USA,Canada	2006	Prospective	880	In-hospital	52	27	18	UNK
de Mos <sup>51</sup>	Canada	2006	Retrospective	91	PICU	82	25	18	UNK
Meaney <sup>38</sup>	USA	2006	Prospective	411	PICU	48.9	21.4	14	UNK
Wu <sup>52</sup>	China	2009	Retrospective	316	In-hospital	72.2	20.9	15.5	UNK
Olotu <sup>53</sup>	Kenya	2009	Prospective	114	In-hospital	UNK	22	ND	UNK
Moreno <sup>54</sup>	Argentina	2010	Prospective	132	PICU	53	19.7	16.6	UNK
Berens <sup>55</sup>	USA	2011	Retrospective	257	In-hospital	56.8	31.1	19.8	UNK
Matos <sup>39</sup>	USA	2013	Retrospective	3419	In-hospital	63.7	27.9	19	UNK
Girotra <sup>11</sup>	USA	2013	Retrospective	1031	In-hospital	UNK	34.8	61	UNK
Zeng <sup>7</sup>	China	2013	Prospective	174	In-hospital	62.1	28.2	86	12.1
López-Herce <sup>4</sup>	Multinational	2013	Prospective	502	In-hospital	69.5	39.2	34.8	UNK
López-Herce <sup>40</sup>	Spain	2014	Prospective	200	In-hospital	74	41	77.9	UNK
Straney <sup>42</sup>	Australia,	2015	Prospective	677	PICU	UNK	63.7	UNK	UNK
	New Zealand								
Rathore <sup>12</sup>	India	2016	Prospective	314	In-hospital	64.6	14	77	11.1
Gupta <sup>46</sup>	USA	2017	Retrospective	154	PICU	100	66.6	94.3	UNK
Andersen <sup>23</sup>	USA	2017	Prospective	182	In-hospital	UNK	53.8	UNK	UNK
Sutton <sup>10</sup>	USA	2018	Prospective	164	PICU	90	47	75.7	UNK
Edward-Jackson <sup>57</sup>	Malawi	2019	Prospective	135	In-hospital	6	0	0	0
Mustafa <sup>58</sup>	England	2021	Retrospective	1528	PICU	UNK	61.9	UNK	UNK
Hamzah <sup>59</sup>	USA	2021	Retrospective	20654	In-hospital	UNK	39.8	UNK	UNK
Lee <sup>33</sup>	China	2022	Retrospective	233	PICU	74.8	25	21.9	UNK
Shimoda-Sakano	Brazil	2022	Prospective	323	In-hospital	70.9	33.7	79.7	28.8
CPR, cardiopulmonary r	esuscitation; N, n	umber o	of patients; ROSC	, return o	of spontaneou	s circulation; I	PICU, pediatric	c intensive care unit; U	NK, unknown.

Table 5 – Characterization	of pediatric in-hospital	CPR (adaptation of L	ópez-Herce, under auth	orization).
----------------------------	--------------------------	----------------------	------------------------	-------------

is a reference in liver transplantation and receive severely ill patients from all over the country. Delayed diagnosis and difficulty in accessing the hospital due to the continental size of Brazil may explain the greater severity.

Although comparison with other studies depends on institutional characteristics, data from children and adults also reported lower survival in cirrhotic patients<sup>35,36</sup> and unfavourable neurological prognosis.<sup>37</sup>

The administration of vasoactive drugs before cardiac arrest was associated with lower survival to hospital discharge and after 180 days along with poorer neurological prognosis. Other authors also have observed the same association with lower survival to hospital discharge<sup>12,33,38</sup>, as well as poorer neurological outcome.<sup>33</sup> The use of vasoactive drug support may reflect patient condition and the association with lower survival rates may be a marker of severity rather than cause-and-effect relationship.

The main causes of cardiac arrest were respiratory (47.4%) and shock (37.5%), aligned to the literature.<sup>1,3,31,39</sup> Shock associated with lower survival to hospital discharge and after 180 days is confirmed by other studies.<sup>23,40</sup> The increasing number of children surviving with severe chronic diseases may explain the mortality due to shock.

The present study showed that the longer the CPR, the lower the survival rate at discharge and after 180 days, both in univariable and multivariable analysis. This influence of CPR duration on prognosis was also observed by other authors.<sup>3,4,9,24,31,39,41,42</sup> A multicentre

registry reported a drop of 2.1% per minute in survival to discharge and of 1.2% per minute in favourable outcome in events which CPR duration was inferior to 15 min.<sup>39</sup> However, it is possible to obtain a good prognosis, even in prolonged CPR. Studies including CPR duration greater than 30 minutes showed favourable neurological outcome in 60% to 89% of CPR events.<sup>9,39</sup> In addition, survival rates of 16.6% has been observed in patients undergoing CPR lasting longer than 35 min.<sup>39</sup>

CPR duration is a variable that is influenced by pre-cardiac arrest and intra-CPR events, and thus should be considered as an important prognostic factor. A child with chronic disease, who has shock and cardiac arrest in asystole, is expected to have longer CPR than a child who develops symptomatic bradycardia due to asphyxia and recover with ventilation, chest compression and one adrenaline dose.

The analysis of adrenaline's role in survival is complex and could not be explored in this study. Data on the time to the first dose, doses interval, and the number of doses are important in the analysis and were not collected in this study. In addition, other factors such as CPR duration and the initial rhythm of cardiac arrest should be considered. Holmberg et al. described in children receiving CPR for bradycardia with poor perfusion that adrenaline was associated with worse outcomes and this, at least partially, explains how complex it is to analyze the influence of adrenaline on survival.<sup>60</sup>

The use of bicarbonate during CPR was frequent and associated with lower survival to hospital discharge and after 180 days. In a

meta-analysis, the use of bicarbonate during in-hospital paediatric cardiac arrest was also frequent (43.7–65.6%) and associated with lower survival to hospital discharge.<sup>43</sup> Despite not being routinely recommended by paediatric resuscitation guidelines,<sup>44,45</sup> it is likely indicated in prolonged cardiac arrest in patients with high complexity or due to lower adherence to advanced life support recommendations.

Neurological outcome was favourable in 76.1% of survivors after 180 days and this result is confirmed by others studies.<sup>3,4,11,31,42,46</sup> Pre-cardiac arrest neurological dysfunction in complex chronic conditions carriers is expected and was present in about one-third (31.4%) of patients. Significant worsening of neurological function (20.2%) occurred between prearrest and discharge periods, but not between discharge and 180-day periods.

Patients with severe prearrest dysfunction (Paediatric Cerebral Performance Category 4) remained unchanged after 180 days. This group may not have had any Paediatric Cerebral Performance Category changes or this score is not sensitive enough to detect worsening brain function in patients with previous severe involvement. The International Liaison Committee on Resuscitation, through the Paediatric Core Outcome Set for Cardiac Arrest (P-COSCA) initiative, suggests the use of the Paediatric Cerebral Performance Category score, despite its limitations, for being validated and extensively used in paediatric CPR studies and for the possibility of being applied to children from birth to 18 years of age.<sup>47</sup>

Among the strengths of this study, some must be highlighted: the study included paediatric patients with complex chronic conditions, an increasingly important population; it was conducted in a middleincome country where epidemiological studies are scarce; it is a robust sample for a single centre; included Paediatric Cerebral Performance Category evaluation prearrest and post-cardiac arrest; and compared data from the current study with a previous one carried out in the same hospital.

Some of the limitations were those inherent to the performance of a study in a single centre, albeit the local validity remains, which may reflect the reality of tertiary and quaternary hospitals in middleincome countries. Although the recording of all CPR have been encouraged, it is not possible to guarantee that data regarding all eligible patients were recorded. Additionally, only the index event was considered, i.e., the first CPR performed in the hospital, and other cardiac arrest events may have negatively influenced survival and neurological outcome. Patients with trauma and surgical cardiac diseases have very specific characteristics and were not included, which may have influenced the comparison with other studies.

# Conclusions

In-hospital paediatric cardiac arrest in patients with complex chronic conditions had lower survival to discharge and after 180 days associated with liver disease, shock as immediate cause of the arrest, vasoactive drug support before cardiac arrest, bicarbonate administration during CPR, and prolonged CPR attempt. Neurological outcome was favourable in most patients and similar in the evaluations performed at discharge and after 180 days.

# **Declaration of conflicts of interest**

Authors have nothing to disclose with regard to commercial support.

#### **Role of the funding source**

The authors have not received any funding for undertaking this work.

#### **Ethics and patient consent**

These were not required for this study.

# **Collaborators**

Tania M Shimoda-Sakano was responsible for data acquisition, analysed data, drafted the article and reviewed the manuscript.

Amelia G Reis was responsible for the conceptualization and designed the study, coordinated and supervised data collection, carried out the initial analyses and critically reviewed the manuscript.

Edison F Paiva supervised data collection, analysed the data, critically reviewed and helped to draft the manuscript.

Claudio Schvartsman revised the data and critically reviewed the manuscript.

All authors approved the final article as submitted, and agree to be accountable for all aspects of the work.

# **Contributors**

Tania M Shimoda-Sakano was responsible for data acquisition, analyzed data, drafted the article and reviewed the manuscript.

Amelia G Reis was responsible for the conceptualization and designed the study, coordinated and supervised data collection, carried out the initial analyses and critically reviewed and the manuscript.

Paiva EF supervised data collection, analysed the data, critically reviewed and helped to draft the manuscript.

Schvartsman C revised the data and critically reviewed the manuscript.

All authors approved the final article as submitted, and agree to be accountable for all aspects of the work.

### **Appendix A. Supplementary material**

Supplementary material to this article can be found online at https://doi.org/10.1016/j.resplu.2022.100354.

# **Author details**

<sup>a</sup>University of Sao Paulo Children Institute, São Paulo, SP, Brazil <sup>b</sup>Hospital das Clínicas, São Paulo, SP, Brazil

#### REFERENCES

- Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. JAMA 2006;295:50–7.
- Holmberg MJ, Ross CE, Fitzmaurice GM, et al. Annual Incidence of Adult and Pediatric In-Hospital Cardiac Arrest in the United States. Circ Cardiovasc Qual Outcomes 2019;12:e005580.

- Reis AG, Nadkarni V, Perondi MB, Grisi S, Berg RA. A prospective investigation into the epidemiology of in-hospital pediatric cardiopulmonary resuscitation using the international Utstein reporting style. Pediatrics 2002;109:200–9.
- López-Herce J, Del Castillo J, Matamoros M, et al. Factors associated with mortality in pediatric in-hospital cardiac arrest: a prospective multicenter multinational observational study. Intensive Care Med 2013;39:309–18.
- Del Castillo J, López-Herce J, Matamoros M, et al. Long-term evolution after in-hospital cardiac arrest in children: Prospective multicenter multinational study. Resuscitation 2015;96:126–34.
- Alten JA, Klugman D, Raymond TT, et al. Epidemiology and Outcomes of Cardiac Arrest in Pediatric Cardiac ICUs. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc 2017;18:935–43.
- Zeng J, Qian S, Zheng M, Wang Y, Zhou G, Wang H. The epidemiology and resuscitation effects of cardiopulmonary arrest among hospitalized children and adolescents in Beijing: an observational study. Resuscitation 2013;84:1685–90.
- Martinez PA, Totapally BR. The epidemiology and outcomes of pediatric in-hospital cardiopulmonary arrest in the United States during 1997 to 2012. Resuscitation 2016;105:177–81.
- Berg RA, Nadkarni VM, Clark AE, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Incidence and Outcomes of Cardiopulmonary Resuscitation in PICUs. Crit Care Med 2016;44:798–808.
- Sutton RM, Reeder RW, Landis W, et al. Chest compression rates and pediatric in-hospital cardiac arrest survival outcomes. Resuscitation 2018;130:159–66.
- Girotra S, Spertus JA, Li Y, et al. Survival trends in pediatric inhospital cardiac arrests: an analysis from Get With the Guidelines-Resuscitation. Circ Cardiovasc Qual Outcomes 2013;6:42–9.
- Rathore V, Bansal A, Singhi SC, Singhi P, Muralidharan J. Survival and neurological outcome following in-hospital paediatric cardiopulmonary resuscitation in North India. Paediatr Int Child Health 2016;36:141–7.
- Morgan RW, Reeder RW, Meert KL, et al. Survival and Hemodynamics During Pediatric Cardiopulmonary Resuscitation for Bradycardia and Poor Perfusion Versus Pulseless Cardiac Arrest. Crit Care Med 2020;48:881–9.
- 14. Junior CJ, Prata-Barbosa A, Lima-Setta F, et al. Brazilian Research in Intensive Care (BRICnet). Prevalence and functional status of children with complex chronic conditions in Brazilian PICUs during the COVID-19 pandemic. J Pediatr (Rio J) 2022;98:484–9.
- Arias López MDP, Fernández AL, Fiquepron K, et al. Prevalence of Children With Complex Chronic Conditions in PICUs of Argentina: A Prospective Multicenter Study. Pediatr Crit Care Med 2020;21: e143–51.
- Feudtner C, Christakis DA, Connell FA. Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington State, 1980–1997. Pediatrics 2000;106:205–9.
- Edwards JD, Houtrow AJ, Vasilevskis EE, et al. Chronic conditions among children admitted to U.S. pediatric intensive care units: their prevalence and impact on risk for mortality and prolonged length of stay\*. Crit Care Med 2012;40:2196–203.
- Shimoda-Sakano TM, Schvartsman C, Reis AG. Epidemiology of pediatric cardiopulmonary resuscitation. J Pediatr (Rio J) 2020;96:409–21.
- Tibballs J, Kinney S. A prospective study of outcome of inpatient paediatric cardiopulmonary arrest. Resuscitation 2006;71:310–8.
- Meert KL, Donaldson A, Nadkarni V, et al. Multicenter cohort study of in-hospital pediatric cardiac arrest. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc 2009;10:544–53.
- 21. Del Castillo J, López-Herce J, Cañadas S, et al. Iberoamerican Pediatric Cardiac Arrest Study Network RIBEPCI. Cardiac arrest and

resuscitation in the pediatric intensive care unit: a prospective multicenter multinational study. Resuscitation 2014;85:1380-6.

- Jayaram N, Spertus JA, Nadkarni V, et al. Hospital variation in survival after pediatric in-hospital cardiac arrest. Circ Cardiovasc Qual Outcomes 2014;7:517–23.
- 23. Andersen LW, Vognsen M, Topjian A, et al. Pediatric In-Hospital Acute Respiratory Compromise: A Report From the American Heart Association's Get With the Guidelines-Resuscitation Registry. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc 2017;18:838–49.
- Suominen P, Olkkola KT, Voipio V, Korpela R, Palo R, Räsänen J. Utstein style reporting of in-hospital paediatric cardiopulmonary resuscitation. Resuscitation 2000;45:17–25.
- 25. Ortmann L, Prodhan P, Gossett J, et al. for the American Heart Association's Get With the Guidelines-Resuscitation Investigators. Outcomes after in-hospital cardiac arrest in children with cardiac disease: a report from Get With the Guidelines-Resuscitation. Circulation 2011;124:2329–37.
- Kleinman ME, Perkins GD, Bhanji F, et al. ILCOR Scientific Knowledge Gaps and Clinical Research Priorities for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: A Consensus Statement. Resuscitation 2018;127:132–46.
- 27. Nolan JP, Berg RA, Andersen LW, et al. Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: Update of the Utstein Resuscitation Registry Template for In-Hospital Cardiac Arrest: A Consensus Report From a Task Force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia). Resuscitation 2019.
- Raymond TT, Carroll TG, Sales G, Morris MC. Effectiveness of the informed consent process for a pediatric resuscitation trial. Pediatrics 2010;125:e866–75.
- Committee on Pediatric Emergency Medicine and Committee on Bioethics. Consent for emergency medical services for children and adolescents. Pediatrics 2011;128:427–33.
- Eltorki M, Uleryk E, Freedman SB. Waiver of informed consent in pediatric resuscitation research: a systematic review. Acad Emerg Med 2013;20:822–34.
- Meert K, Telford R, Holubkov R, et al. Paediatric in-hospital cardiac arrest: Factors associated with survival and neurobehavioural outcome one year later. Resuscitation 2018;124:96–105.
- Rodríguez-Núñez A, López-Herce J, del Castillo J, Bellón JM. Iberian-American Paediatric Cardiac Arrest Study Network RIBEPCI. Shockable rhythms and defibrillation during in-hospital pediatric cardiac arrest. Resuscitation 2014;85:387–91.
- Lee EP, Chan OW, Lin JJ, Hsia SH, Wu HP. Risk Factors and Neurologic Outcomes Associated With Resuscitation in the Pediatric Intensive Care Unit. Front Pediatr 2022;10 834746.
- Perondi MBM, Reis AG, Paiva EF, Nadkarni VM, Berg RA. A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest. N Engl J Med 2004;350:1722–30.
- 35. Knudson JD, Neish SR, Cabrera AG, et al. Prevalence and outcomes of pediatric in-hospital cardiopulmonary resuscitation in the United States: an analysis of the Kids' Inpatient Database\*. Crit Care Med 2012;40:2940–4.
- Oud L. In-hospital cardiopulmonary resuscitation of patients with cirrhosis: A population-based analysis. PLoS One 2019;14: e0222873.
- 37. Levy PD, Ye H, Compton S, Chan PS, Larkin GL, Welch RD. American Heart Association National Registry of Cardiopulmonary Resuscitation Investigators. Factors associated with neurologically intact survival for patients with acute heart failure and in-hospital cardiac arrest. Circ Heart Fail 2009;2:572–81.
- Meaney PA, Nadkarni VM, Cook EF, et al. Higher survival rates among younger patients after pediatric intensive care unit cardiac arrests. Pediatrics 2006;118:2424–33.

- Matos RI, Watson RS, Nadkarni VM, et al. Duration of cardiopulmonary resuscitation and illness category impact survival and neurologic outcomes for in-hospital pediatric cardiac arrests. Circulation 2013;127:442–51.
- López-Herce J, del Castillo J, Cañadas S, Rodríguez-Núñez A, Carrillo A. Spanish Study Group of Cardiopulmonary Arrest in Children. In-hospital pediatric cardiac arrest in Spain. Rev Esp Cardiol (Engl Ed) 2014;67:189–95.
- Rodríguez-Núñez A, López-Herce J, del Castillo J, Bellón JM, Iberian-American Paediatric Cardiac Arrest Study Network RIBEPCI. Shockable rhythms and defibrillation during in-hospital pediatric cardiac arrest. Resuscitation 2014;85:387–91.
- 42. Straney LD, Schlapbach LJ, Yong G, et al. Trends in PICU Admission and Survival Rates in Children in Australia and New Zealand Following Cardiac Arrest. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc 2015;16:613–20.
- Chang CY, Wu PH, Hsiao CT, Chang CP, Chen YC, Wu KH. Sodium bicarbonate administration during in-hospital pediatric cardiac arrest: A systematic review and meta-analysis. Resuscitation 2021:162:188–97.
- 44. Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2020;142(16\_suppl\_2):S469–523.
- 45. Van de Voorde P, Turner NM, Djakow J, et al. European Resuscitation Council Guidelines 2021: Paediatric Life Support. Resuscitation 2021;161:327–87.
- Gupta P, Wilcox A, Noel TR, et al. Characterizing cardiac arrest in children undergoing cardiac surgery: A single-center study. J Thorac Cardiovasc Surg fevereiro de 2017;153:450–458.e1.
- 47. Topjian AA, Scholefield BR, Pinto NP, et al. P-COSCA (Pediatric Core Outcome Set for Cardiac Arrest) in Children: An Advisory Statement From the International Liaison Committee on Resuscitation. Resuscitation 2021;162:351–64.
- Slonim AD, Patel KM, Ruttimann UE, Pollack MM. Cardiopulmonary resuscitation in pediatric intensive care units. Crit Care Med 1997;25:1951–5.
- 49. Guay J, Lortie L. An evaluation of pediatric in-hospital advanced life support interventions using the pediatric Utstein guidelines: a review

of 203 cardiorespiratory arrests. Can J Anaesth J Can Anesth 2004;51:373-8.

- Rodríguez-Núñez A, López-Herce J, García C, et al. Pediatric defibrillation after cardiac arrest: initial response and outcome. Crit Care Lond Engl 2006;10:R113.
- de Mos N, van Litsenburg RRL, McCrindle B, Bohn DJ, Parshuram CS. Pediatric in-intensive-care-unit cardiac arrest: incidence, survival, and predictive factors. Crit Care Med 2006;34:1209–15.
- Wu E-T, Li M-J, Huang S-C, et al. Survey of outcome of CPR in pediatric in-hospital cardiac arrest in a medical center in Taiwan. Resuscitation 2009;80:443–8.
- Olotu A, Ndiritu M, Ismael M, et al. Characteristics and outcome of cardiopulmonary resuscitation in hospitalised African children. Resuscitation 2009;80:69–72.
- 54. Moreno RP, Vassallo JC, Sáenz SS, et al. Estudio colaborativo multicéntrico sobre reanimación cardiopulmonar en nueve unidades de cuidados intensivos pediátricos de la República Argentina: A multicentric study [Cardiopulmonary resuscitation in nine pediatric intensive care units of the Argentine Republic]. Arch Argent Pediatr 2010;108:216–25.
- Berens RJ, Cassidy LD, Matchey J, et al. Probability of survival based on etiology of cardiopulmonary arrest in pediatric patients. Paediatr Anaesth 2011;21:834–40.
- Edwards-Jackson N, North K, Chiume M, et al. Outcomes of inhospital paediatric cardiac arrest from a tertiary hospital in a lowincome African country. Paediatr Int Child Health 2019:1–5.
- 58. Mustafa K, Buckley H, Feltbower R, Kumar R, Scholefield BR. Epidemiology of Cardiopulmonary Resuscitation in Critically III Children Admitted to Pediatric Intensive Care Units Across England: A Multicenter Retrospective Cohort Study. J Am Heart Assoc 2021;10:e018177.
- Hamzah M, Othman HF, Almasri M, Al-Subu A, Lutfi R. Survival outcomes of in-hospital cardiac arrest in pediatric patients in the USA. Eur J Pediatr 2021;180:2513–20.
- Holmberg MJ, Ross CE, Yankama T, Roberts JS, Andersen LW. Epinephrine in children receiving cardiopulmonary resuscitation for bradycardia with poor perfusion. Resuscitation 2020;149:180–90.